Nal-IRI Improves Second-Line Outcomes in Pancreatic Cancer : Pancreatology | June 2026

Introduction:

Despite advances in systemic therapy, metastatic and recurrent pancreatic cancer remains associated with poor survival. Following progression on first-line gemcitabine-based chemotherapy, treatment options have historically been limited. The introduction of nanoliposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin (5-FU/LV) represented an important therapeutic advance, demonstrating improved efficacy in clinical trials. However, whether this benefit translates into routine clinical practice has remained uncertain.

Problem Statement:

Clinical trial populations often differ from real-world patients encountered in daily oncology practice. Consequently, it is important to determine whether the availability of nal-IRI has meaningfully improved survival outcomes for patients with metastatic or recurrent pancreatic cancer outside controlled trial settings.

Summary:

This real-world study compared treatment outcomes in patients with metastatic or recurrent pancreatic cancer before and after the introduction of nal-IRI plus 5-FU/LV as a second-line treatment option. The investigators found that while overall survival from the start of first-line therapy remained largely unchanged, patients treated in the era following nal-IRI availability experienced significantly improved outcomes after progression on first-line treatment. Both progression-free survival and overall survival from initiation of second-line therapy were prolonged following the introduction of nal-IRI-based treatment. Furthermore, multivariable analysis identified treatment in the nal-IRI era as an independent predictor of improved second-line survival. These findings suggest that access to effective second-line therapy can meaningfully influence outcomes even in a disease with historically limited treatment options. Importantly, the survival benefits were achieved with an acceptable safety profile, supporting the feasibility of this regimen in routine practice. The study provides valuable real-world evidence confirming that the benefits observed in clinical trials can be translated into everyday clinical care. Overall, the results support nal-IRI plus 5-FU/LV as an important component of the treatment sequence for metastatic and recurrent pancreatic cancer and highlight the growing importance of effective second-line therapy in improving patient outcomes.